(Q36489754)

14 August 2017

1 reference

title

Oral cholera vaccines: use in clinical practice (English)

1 reference

14 August 2017

0 references

David G Lalloo

3

0 references

author name string

David R Hill

series ordinal

1

1 reference

PubMed ID

16728322

14 August 2017

Lisa Ford

series ordinal

2

1 reference

14 August 2017

1 June 2006

1 reference

Lancet Infectious Diseases

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

6

1 reference

14 August 2017

361-373

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

14 August 2017

1 reference

7 January 2021

Cholera: assessing the risk to travellers and identifying methods of protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Microbial-gut interactions in health and disease. Progress in enteric vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemic Cholera in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Clinical profile of acute diarrhoea cases infected with the new epidemic strain of Vibrio cholerae O139: designation of the disease as cholera

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

1 reference

7 January 2021

Rapid emergence of El Tor Vibrio cholerae resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Emergence of multiple drug resistance in Vibrio cholerae O1 El Tor from Ecuador

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

The three-dimensional crystal structure of cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

1 reference

7 January 2021

Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Endemic cholera in rural Bangladesh, 1966-1980.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Biotype as determinant of natural immunising effect of cholera

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemic and endemic cholera trends over a 33-year period in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Duration of infection-derived immunity to cholera

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Risk of Cholera Among Western and Japanese Travelers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

1 reference

7 January 2021

Reported cholera in the United States, 1992-1994: a reflection of global changes in cholera epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemiology of cholera in travellers, and conclusions for vaccination recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemiology of travelers' diarrhea and relative importance of various pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Cholera among Americans living in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Ineffectiveness of cholera vaccination as an epidemic control measure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Field trial of oral cholera vaccines in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Effectiveness of mass oral cholera vaccination in Beira, Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Onset and Duration of Protective Immunity in Challenged Volunteers after Vaccination with Live Oral Cholera Vaccine CVD l03-HgR

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Live oral vaccines against cholera: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Can oral cholera vaccination play a role in controlling a cholera outbreak?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Prevention and treatment of traveler's diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Risk and aetiology of diarrhoea at various tourist destinations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemiology of diarrhea in travelers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Pathogens that cause travelers' diarrhea in Latin America and Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemiology of travelers' diarrhea: current perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enteroaggregative Escherichia coli: an emerging enteric pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Diarrheagenic Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

To know Escherichia coli is to know bacterial diarrheal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Pathogenic enteric Escherichia coli in children with and without diarrhea in Maputo, Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Outbreaks of cholera-like diarrhoea caused by enterotoxigenic Escherichia coli in the Brazilian Amazon Rainforest.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

High Disease Burden of Diarrhea Due to Enterotoxigenic Escherichia coli among Rural Egyptian Infants and Young Children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enterotoxigenic Escherichia coli and Vibrio cholerae diarrhea, Bangladesh, 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Colonization factors of human enterotoxigenic Escherichia coli (ETEC).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Escherichia coli enterotoxin (STa) binds to receptors, stimulates guanyl cyclase, and impairs absorption in rat colon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Infection with colonization factor antigen I-expressing enterotoxigenic Escherichia coli boosts antibody responses against heterologous colonization factors in primed subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemiologic Observations on Diarrhea Developing in U.S. and Mexican Students Living in Guadalajara, Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Etiology of travelers' diarrhea on a Caribbean island.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Traveler's diarrhea at sea: three outbreaks of waterborne enterotoxigenic Escherichia coli on cruise ships

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enterotoxin-producing bacteria isolated from Swedish travellers with diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Characterization of enterotoxigenic Escherichia coli strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992-1997

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Epidemiology of diarrhea among expatriate residents living in a highly endemic environment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Clinical features and duration of traveler's diarrhea in relation to its etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Isolation of enterotoxigenic Escherichia coli from British troops in Saudi Arabia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Diarrheal disease among military personnel during Operation Restore Hope, Somalia, 1992-1993.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Etiology of acute diarrhea among United States military personnel deployed to South America and west Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Oral cholera vaccine well tolerated

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Traveller's diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

Guide to development of practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970494-7

7 January 2021

10.1016/S1473-3099(06)70494-7

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16728322